Desirée Campoy

Mum and Hematologist interesed in thrombosis and hemostasis disorders 💉🔬💊 LOVE my job, family and friends. I am always planning a trip 🌎🌎 -Vall d'Hebron-

[Ahmed Kotb @AhmedKo45911157]

🩸Atypical-Site Thrombosis – Risk Factors
🧬Hereditary: Factor V Leiden, Prothrombin, Prot C/S, ATIII
���Acquired: MPNs (JAK2), PNH, APLS, Cancer
⚠️Others: Pregnancy, hormones, IBD, meds (heparin, L-asp), cocaine

Know triggers👉Think beyond DVT/PE!
#Thrombosis #HemeTwitter #ASH

[Desirée Campoy @CampoyDesiree]

Again super proud!

[peoliver @pavel_olivera]

Orgulloso de cerrar #ISTH2025 con la brillante presentación de Marina Serra que destacó por su alto nivel científico y claridad
Desde @Hemato_Vhebron aportamos evidencia clave en un escenario clínico complejo y generamos debate científico de alto nivel
@isth @SETH__Oficial @VHIO

[Desirée Campoy @CampoyDesiree]

Super proud!!

[Olga Benítez @oBenitez6]

La Dra. Serra, residente de @Hemato_Vhebron y becada por la @SETH__Oficial, presentó en #ISTH2025 una destacada comunicación oral sobre prevención secundaria en trombosis venosa portal.
#SETHJoven #SomosSETH
@isth @SEHHJoven

[Alex Spyropoulos @AlexSpyropoul]

Standardized #periprocedural management of #DOACs is the path forward: https://t.co/WuZo3s23Z8 @Vasculearn @AnticoagForum @PERTConsortium @canvector @ThrombosisCan @ThrombosisUK @EuropeanTHA @thrombosisday @escardio

[RPTH @RPTHjournal]

Caring for Von Willebrand Disease?

Read this state-of-the-art review which summarizes current and emerging therapies for the most common bleeding disorder:

https://t.co/fSLWOrCkDH

[Marc Carrier @MarcCarrier1]

@ASH_hematology Late Breaking Abstract:
Should patients receive extended duration anticoagulation with reduced or full dose DOAC for the secondary prevention of recurrent VTE - The RENOVE RCT presented by @FCouturaud
Reduced dose DOAC was not non inferior to full dose ((5-year cumulative incidence 2.2% vs 1.8%, P=0.23 for noninferiority) but lower risk of clinically relevant bleeding (9.9 vs 15.2%)! 🩸
Risk benefit seems to favor reduced dosing for most patients #ASH24

[Saskia Middeldorp @MiddeldorpS]

Is it allowed to say we had a fantastic educational session on #hormone related #VTE with Dr Leslie Skeith and Dr Joseph Shatzel #ASH24? A packed room and loads of interaction. Sorry we couldn’t handle all online questions 🤷🏻‍♀️.

[Marc Carrier @MarcCarrier1]

Dr. @LeaderAvi provided a great review on initiation of anticoagulation in patients with brain metastatic disease. No difference between LMWH and DOACs and management needs to be tailored based on risk of ICH (risk factors and MRI findings)
#ASH24

[Marc Carrier @MarcCarrier1]

Superficial vein thrombosis of the upper extremity are common in cancer patients. They are often managed conservatively.

@LaurenTokes presented her summer project at #ASH24 and showed that the risk of extension and recurrence is relatively high. This needs to be balance with bleeding 🩸

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm @ASH_hematology

Treatment of VTE in the thrombocytopenic cancer patient

Guidelines for treatment of VTE in patients with thrombocytopenia

[Marc Carrier @MarcCarrier1]

Many anticoagulant-related bleedings 🩸 in patients with cancer are attributable to modifiable risk factors. Addressing them (anemia, HTN, anti platelets, alcohol abuse) could improve outcomes in these patients!
@KSanfilippoMD #ASH24

[Desirée Campoy @CampoyDesiree]

Congratulations Marina! Thanxs @pavel_olivera for building the best team!

[peoliver @pavel_olivera]

#ASH24 Low-dose DOACs superior to VKA for long-term prevention of portal vein thrombosis (PVT) in cirrhosis. VKA tripled major bleeding risk 🩸 vs. low-dose DOACs. Favors low-dose DOACs over VKA for anticoagulation in cirrhotic PVT. @SETH__Oficial @Hemato_Vhebron 💪🏼 #Proudteam

[Alex Spyropoulos @AlexSpyropoul]

Periprocedural data with #FXI inhibitor abelacimab promising, but more work in high #bleeding risk/urgent surgeries needed @NATFthrombosis @AnticoagForum @ThrombosisCan @canvector @ThrombosisUK @TromboseLeiden @thrombosisday @EuropeanTHA @escardio

[Olga Benítez @oBenitez6]

El Dr. Sergi Camarillas, residente de @Hemato_Vhebron 🥇 al mejor póster presentado en el IX Curso de Coagulopatias de Baeza

[Dini Khairani @CandrikaDini]

2/ The efficacy and safety of DOACs also remain uncertain for several other indications:

[Behnood Bikdeli @bbikdeli]

🙏🙏 amazing team/ experts: @aliassi19 @psadeghipour @AzitaTalasaz @MiddeldorpS @MaryCushmanMD @GregoryPiazza4 @connors_md @DebSiegal @GBarnesMD @mmonrealriete @DJC6998 @MitchElkind @dkleindo @hmkyale @Drroxmehran @RenatoDLopes1
A practical algorithm: https://t.co/YMuIAhJlOL 👇

[Behnood Bikdeli @bbikdeli]

@aliassi19 @psadeghipour @AzitaTalasaz @MiddeldorpS @MaryCushmanMD @GregoryPiazza4 @connors_md @DebSiegal @GBarnesMD @mmonrealriete @DJC6998 @MitchElkind @dkleindo @hmkyale @Drroxmehran @RenatoDLopes1 @JACCJournals If there is no thrombotic APS, mechanical valves, LVAD, pregnancy/breastfeeding, no 📛📛 concern for DOACs. Still, carefully think about ESRD, catheter-associated VTE, CVST, LV clots, or ACHD. Discuss potential risks and benefits before proceeding w DOACs vs alternatives. 👇

[Desirée Campoy @CampoyDesiree]

Attention!

[Dini Khairani @CandrikaDini]

1/ DOACs are preferred for prevention or treatment of thromboembolism in most patients with AF or VTE.

However, it should not be the standard treatment for patients with mechanical heart valves, atrial fibrillation with rheumatic mitral stenosis, or anti- phospholipid syndrome.

[Desirée Campoy @CampoyDesiree]

Resumen iconográfico de ACODs en VTE en situaciones especiales

[SETH Trombosis y Hemostasia @SETH__Oficial]

🩸Uso de #anticoagulantes 💊 orales directos para el tratamiento del #tromboembolismo venoso en extremos de peso corporal, función renal y hepática: una revisión ilustrada @RPTHjournal

👉https://t.co/yRSv5rEsxD

[Mahé Isabelle @isabellemahe1]

VTE #RECURRENCE IN #CAT PATIENTS : a persistent unmet need for clinicians. New data about management and evolution from a large nationwide cohort study.#ASH2023 @LaurentBertole1 @INNOVTE1